Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNE ...

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 ...

Almost 90% of a cohort of patients with systemic lupus erythematosus reported experiencing depression or depressive symptoms ...

The prevalence of SSc among Alaska Native and American Indian adults is comparable to or higher than other populations, with high GI and pulmonary involvement.

Emerging multiomic profiling is providing insights into the unique molecular features of brain metastases and potential targetable pathways. Molecular analysis of metastases, whenever possible, should ...

The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release. Nipocalimab ...

Diffuse intrinsic pontine glioma (DIPG) is a rare, aggressive brain stem tumor that usually affects children ages 5 to 10. It forms where the brain connects to the spine, which controls breathing, ...

Family of Black girls handcuffed, held at gunpoint by Colorado police reach $1.9 million settlement A Black woman and a group of young girls who were wrongfully forced out of their car, held at ...

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma A systematic review, one meta-analysis, and 34 additional randomized trials were identified. The published studies ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.